Atrasentan (ABT-627) is an endothelin A antagonist being investigated for the treatment of diabetic nephropathy in Type 2 diabetic patients.

Type of Molecule

Small Molecule

Target

Endothelin

Region

n/a

Potential Indication Product Type Phase (1, 2, 3, Submitted, Approved)
Diabetic Nephropathy New Indication Phase 3